For the year ending 2025-12-31, IMNM had $510,241K increase in cash & cash equivalents over the period. -$200,604K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -212,394 |
| Depreciation and amortization | 2,466 |
| Amortization of right-of-use asset | 489 |
| Accretion of discounts on marketable securities | 2,839 |
| Share-based compensation expense | 25,690 |
| Loss on disposal of property and equipment | -896 |
| Charge for purchase of in-process research and development assets, including upon achievement of milestones | 10,000 |
| Prepaid expenses and other assets | 3,489 |
| Accounts payable | -9,164 |
| Accrued expenses and other current liabilities | 4,533 |
| Deferred revenue | -6,941 |
| Operating lease liabilities | -166 |
| Net cash used in operating activities | -190,919 |
| Maturities of marketable securities | 200,000 |
| Purchases of marketable securities | 123,266 |
| Purchases of property and equipment | 9,685 |
| Purchases of in-process research and development assets | 6,246 |
| Net cash provided by (used in) investing activities | 60,803 |
| Proceeds from public offerings | 633,003 |
| Proceeds from issuance of common stock under atm | 45,897 |
| Payment of offering costs | 39,456 |
| Proceeds from exercise of stock options | 913 |
| Proceeds from exercise of common stock warrants | 0 |
| Net cash provided by financing activities | 640,357 |
| Net increase in cash and cash equivalents and restricted cash | 510,241 |
| Cash and cash equivalents and restricted cash at beginning of period | 143,451 |
| Cash and cash equivalents and restricted cash at end of period | 653,692 |
IMNM
IMNM